News and Announcements
Select 3D is a pioneer in the $27B industry of 3D printing with multiple near term commercial avenues
- Published March 31, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
“We all come in different sizes, shapes, colours and hold different possessions. Even businesses have varying requirements. Sometimes an off the shelf product does not suit. Matching the requirement with a custom or bespoke manufactured product is our aim for consumers as they resize or change, similarly for businesses and government as their needs change.
Select 3D is a 3D technology, 3D printing/manufacturing, mixed reality and consultancy company.”
Anuja Rao, Founder, Select 3D Pty Ltd
Executive Summary
Select3D is establishing the leading commercial 3D printing consultancy and production house and mixed reality platform in Australia. 3D printing is a rapidly growing industry with multiple commercial interests and use-cases.
- 3D printing is a fast growing market, currently a $27B industry alone.
Select3D provides reliable 3D printing services and products combined alongside a scalable mixed reality platform for online shopping. - Clear roadmap for growth across five key sectors – each with multiple opportunities for 3D products.
- There are near-term commercial opportunities/pathways via designer face shields as a product line.
- Developed for Australia’s first and largest full colour 3D printed plaster-like light pendant December 2018.
- Attracted seed investors since 2015.
- Chosen and moved into a government-sponsored incubator.
- Invited to speak on the topic of 3D printing at PASA events.
Investment Offering
Select 3D is initially raising $250K to fund a pressing opportunity creating covid-19 critical face shields. This will be followed by $11.5M raise, which is required to support the companies long-term growth and attain government matching funds.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
